uniQure (QURE) has just wrapped up FY 2025 with fourth quarter revenue of US$5.6 million and a basic EPS loss of US$0.59, as net income excluding extra items came in at a loss of US$37.1 million. Over recent quarters, the company has seen revenue move between US$1.6 million and US$5.6 million while basic EPS ranged from a loss of US$0.59 to a loss of US$1.38. This gives investors a clear picture of a business that is still in heavy investment mode rather than focused on near term profitability. With the share price around US$10.50 and margins still under pressure, the latest results put the spotlight squarely on how quickly the revenue base can scale against continued losses.

See our full analysis for uniQure.

With the headline numbers on the table, the next step is to see how this earnings print lines up with the big stories already priced into QURE, and where the data pushes back against the prevailing narratives.

US$199 million of losses on a US$16 million revenue base

• Over the last twelve months to Q4 2025, QURE generated US$16.1 million of revenue against a net loss of US$199.0 million, so the company is still very much in spending mode to build out its gene therapy pipeline.
• Bulls point to the roughly 51% forecast annual revenue growth as the key offset to these losses, but the gap is wide enough that execution has to be very strong over time.
  • Bullish views highlight AMT-130 for Huntington's disease and other programs like AMT-260 and AMT-191 as potential future revenue sources, yet current quarterly revenue between US$1.6 million and US$5.6 million shows that commercial scale is still ahead.
  • Supporters also mention guidance that existing cash can fund operations into 2029, which gives time for those programs to advance, while the latest twelve month loss of US$199.0 million underlines how reliant the story is on that funding runway.

Bulls argue that these losses are the price of building a first mover gene therapy portfolio and that the real question is whether programs like AMT-130 can eventually justify the spend. If you want to see how that optimistic case is built out in full, check out the 🐂 uniQure Bull Case

High P/S multiple with a big DCF gap

• QURE trades on a P/S of 40.6x compared to 12.5x for the US biotechs industry and 26.6x for peers, while the DCF fair value cited for the company sits at about US$592.47, far above the current share price of US$10.50.
• Bears focus on this mix of a very high sales multiple and a very large modelled DCF gap as a sign that expectations are already ambitious even though the business is loss making.
  • Cautious views argue that with the company still posting trailing twelve month EPS of a US$3.46 loss and net losses near US$199.0 million, it is hard to rely on long range DCF outputs without clearer progress toward positive margins.
  • Critics also point out that valuation scenarios in the bearish narrative require very high future P/E multiples on relatively modest earnings, which lines up with the current premium P/S of 40.6x and keeps valuation risk front and center.

Skeptical investors suggest the current valuation already prices in a lot of future success. If you want to see how the more cautious case frames those risks in detail, have a look at the 🐻 uniQure Bear Case

Volatile share price and dilution alongside growth forecasts

• The shares have been highly volatile over the past three months, and investors were diluted over the past year, even as analysts point to around 51% forecast annual revenue growth from this small base.
• The balanced, more consensus style narrative weighs that strong growth outlook against execution and funding risks that show up in the recent volatility and dilution.
  • Consensus commentary flags that QURE is expected to remain unprofitable for at least the next three years, so any new equity issuance to support a pipeline where quarterly net losses have ranged from about US$37.1 million to US$80.5 million directly affects existing holders.
  • At the same time, the presence of several programs and a funded runway gives the company shots on goal, and recent swings in the US$10.50 share price illustrate how sensitive the stock can be to updates on trials, regulation, or financing.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for uniQure on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Reading all this, you can see both enthusiasm and concern in the story, so take a moment to review the numbers yourself and form your own stance, then check out 2 key rewards and 3 important warning signs to see how those potential upsides compare with the issues on investors' minds.

Explore Alternatives

QURE is still posting sizeable losses of US$199.0 million on just US$16.1 million of revenue, with volatility, dilution and premium valuation metrics all weighing on confidence.

If this mix of steep losses, funding reliance and price swings feels uncomfortable, you can quickly compare it with 76 resilient stocks with low risk scores that focus on more resilient profiles today.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.